Device Trial Radar · NCT03894033
Post-market Registry of the AMDS for the Treatment of Acute DeBakey Type I Dissection
Last checked: Nov 20, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
301
Actual
Start
Mar 12, 2019
Primary completion
Jun 30, 2026
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- JOTEC GmbHNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 28, 2019
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this registry is to collect information on the performance and clinical benefits of the AMDS (Ascyrus Medical Dissection Stent) to treat patients with acute "DeBakey type I dissections" and with or without so called "preoperative clinically relevant malperfusion" and/or "intramural hematomas". In a healthy aorta (the vessel that supplies blood to most of the body) the blood flows freely through the main lumen (a space inside the vessel where blood flows). The participants involved in this study have a tear that has separated the inner layer of the aorta wall and created a secondary channel (false lumen) in addition to the main channel (true lumen), and huts, the blood flows through both channels. AMDS is a stent (a metal tube helping to keep the vessel open) that is placed in the descending thoracic aorta. AMDS is a medical device commercially available in the countries in which the study is being conducted and it is used as standard of care according to its indication.
Conditions
- Aortic Dissection
- Acute DeBakey I Dissection
- Acute Type A Dissection
- Intramural Hematoma
Interventions
Ascyrus Medical Dissection Stent (AMDS)Device
The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive arch remodelingTime frame: 3-6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Deutsches Herzzentrum der Charité
Berlin, State of Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.